Zai Lab Stock Today

ZLAB Stock  USD 17.48  0.23  1.30%   

Performance

Weakest

 
Weak
 
Strong

Odds Of Distress

Small

 
High
 
Low
Zai Lab is trading at 17.48 as of the 24th of December 2025, a 1.3 percent decrease since the beginning of the trading day. The stock's open price was 17.71. Zai Lab has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 4th of January 2024 and ending today, the 24th of December 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
20th of September 2017
Category
Healthcare
Classification
Health Care
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China. The company has 110.59 M outstanding shares of which 5.04 M shares are at this time shorted by private and institutional investors with about 5.1 trading days to cover. More on Zai Lab

Moving together with Zai Stock

  0.92AVH Avita MedicalPairCorr
  0.66ROQ Roquefort Investments PLCPairCorr

Moving against Zai Stock

  0.93NHIC NewHold Investment CorpPairCorr
  0.92ACW Actinogen MedicalPairCorr
  0.89JBHT JB Hunt TransportPairCorr
  0.88MTC MMTEC Inc Tech BoostPairCorr
  0.86AAPL Apple IncPairCorr
  0.85AMGN Amgen IncPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Zai Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President DevelopmentRafael MD
Thematic IdeaCancer Fighters (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Golden Dragon, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.350.3365
Sufficiently Up
Slightly volatile
Gross Profit Margin0.730.6294
Fairly Up
Very volatile
Total Current Liabilities314.4 M299.4 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total29.3 M45.5 M
Way Down
Very volatile
Total Assets809.5 M1.2 B
Way Down
Slightly volatile
Total Current Assets739.3 M1.1 B
Way Down
Slightly volatile
Debt Levels
Zai Lab can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Zai Lab's financial leverage. It provides some insight into what part of Zai Lab's total assets is financed by creditors.
Liquidity
Zai Lab currently holds 153.47 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Zai Lab has a current ratio of 7.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Zai Lab's use of debt, we should always consider it together with its cash and equity.

Sale Purchase Of Stock

(7.53 Million)
Zai Lab (ZLAB) is traded on NASDAQ Exchange in USA and employs 1,869 people. Zai Lab is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.96 B. Zai Lab conducts business under Biotechnology sector and is part of Health Care industry. The entity has 110.59 M outstanding shares of which 5.04 M shares are at this time shorted by private and institutional investors with about 5.1 trading days to cover. Zai Lab currently holds about 1.26 B in cash with (214.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.1.
Check Zai Lab Probability Of Bankruptcy
Ownership Allocation
Zai Lab retains a total of 110.59 Million outstanding shares. 30% of Zai Lab outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Zai Ownership Details

Zai Stock Institutional Holders

InstituionRecorded OnShares
Mpm Oncology Impact Management Lp2025-06-30
745.1 K
Jennison Associates Llc2025-06-30
592.3 K
Cam Group Holding A/s2025-06-30
510 K
Blackrock Inc2025-06-30
455.3 K
B Group, Inc2025-06-30
400 K
Connor Clark & Lunn Inv Mgmt Ltd2025-06-30
387.4 K
Citadel Advisors Llc2025-06-30
366.2 K
Xy Capital Ltd2025-06-30
362.6 K
Morgan Stanley - Brokerage Accounts2025-06-30
289.1 K
Fmr Inc2025-06-30
6.2 M
Capital World Investors2025-06-30
M
View Zai Lab Diagnostics

Zai Lab Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Zai Lab market risk premium is the additional return an investor will receive from holding Zai Lab long position in a well-diversified portfolio.

Zai Stock Against Markets

Zai Lab Corporate Management

Peter HuangChief OfficerProfile
Dr MBAChief OfficerProfile
Joshua SmileyChief OfficerProfile
Frazor IIIChief SecProfile
Christine ChiouSenior RelationsProfile
Harald MDAutoimmune NeuroscienceProfile

Already Invested in Zai Lab?

The danger of trading Zai Lab is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zai Lab is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zai Lab. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zai Lab is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zai Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zai Lab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zai Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zai Lab Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zai Lab. If investors know Zai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zai Lab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.90)
Revenue Per Share
4.106
Quarterly Revenue Growth
0.135
Return On Assets
(0.13)
Return On Equity
(0.29)
The market value of Zai Lab is measured differently than its book value, which is the value of Zai that is recorded on the company's balance sheet. Investors also form their own opinion of Zai Lab's value that differs from its market value or its book value, called intrinsic value, which is Zai Lab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zai Lab's market value can be influenced by many factors that don't directly affect Zai Lab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zai Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zai Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zai Lab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.